Heterocyclic compounds as antiviral drugs: Synthesis, structure-activity relationship and traditional applications

Autor(es)

dos Santos, Giovanny Carvalho ^[1] ; Martins, Lucas Michelao ^[2] ; Bregadiolli, Bruna Andressa ^[2] ; Moreno, Vitor Fernandes ^[1] ; da Silva-Filho, Luiz Carlos ^[1] ; Sacoman Torquato da Silva, Bruno Henrique ^[3]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ UNESP, Sch Sci, Dept Chem, Bauru, SP - Brazil

^[2] Sao Paulo State Univ UNESP, Inst Chem, Araraquara, SP - Brazil

^[3] Fed Univ Uberlandia UFU, Inst Chem, BR-38408144 Uberlandia, MG - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: Journal of Heterocyclic Chemistry; v. 58, n. 12 AUG 2021.
• Citações Web of Science: 0

Resumo

A virus outbreak challenges the economic, medical, and public health infrastructure worldwide. More than one virus capable of triggering diseases have been identified per year since 1972, which requires the development of new ways of treatment and prevention, however, such processes are not rapid and easy. With the pandemic scenario experienced since early 2020, several drugs with well-known purposes have gained prominence, due to speculation of their use in the treatment against the new coronavirus. Among the main drugs studied, the vast majority contain a heterocyclic structure. In this review, we presented the traditional and efficient synthesis of 15 drugs that have been studied for the COVID-19 treatment, containing in their structure heterocycles like indole, quinoline, pyrimidone, tetrahydrofuran, pyrrolidine, triazole, pyridazine, pyrazole, pyrrolopyrimidine, azetidine, pyrrolotriazine, pyrazine, tetrahydropyran, benzofuran, spiroketal, and thiazole. Furthermore, we have shown the original applications, as well as their structure-activity relationship and what is their situation as a drug candidate against COVID-19. Thus, the objective was to consolidate the main synthetic and pharmacological aspects involving clinically developed heterocycles that at some point were presented as promising against SARS-CoV-2. (AU)

• Processo FAPESP: 18/14506-7 - Estudo sobre a síntese "one-pot" e aplicação como corantes orgânicos de derivados quinolínicos e antrazolínicos
• Beneficiário: Luiz Carlos da Silva Filho
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 18/09235-4 - Síntese de óxido de grafeno reduzido modificado com derivados de Quinolina para aplicações em células solares.
• Beneficiário: Lucas Michelão Martins
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 17/07627-0 - Síntese de derivados conjugados de óxido de grafeno reduzido-politiofeno para aplicação como HTM em células solares de perovskita
• Beneficiário: Bruna Andressa Bregadiolli
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado